Showing 2281-2290 of 5771 results for "".
- Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-early-assignment-of-permanent-and-specific-j-code-for-dextenza/2476773/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dextenza (dexamethasone ophthalmic insert) 0.4 mg, which is approved for the
- EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code for Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-early-assignment-of-permanent-and-specific-j-code-for-yutiq/2476769/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code, J7314, through the Healthcare Common Procedure Coding System (HCPCS) for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micr
- Oyster Point Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-phase-3-clinical-trial-of-nasal-spray-for-dry-eye-disease/2476763/Oyster Point Pharma announced enrollment of the first subject in the phase 3 ONSET-2 clinical trial of OC-01 nasal spray for the treatment of the signs and symptoms of dry eye disease. “After successfully compl
- Iveric bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapyhttps://modernod.com/news/iveric-bio-announces-successful-advancement-of-lca10-minigene-program-and-expansion-of-orphan-gene-therapy/2476762/Iveric bio announced that the company has exercised its option and entered into an exclusive global license agreement with the University of Massachusetts Medical School for rights to develop and commercialize mutation independent novel adeno-associated virus (AAV) gene therapy product candidates
- Glaukos Announces Global Licensing Agreement With Intratus, Maker of Noninvasive Drug Delivery Platformhttps://modernod.com/news/glaukos-announces-global-licensing-agreement-with-intratus/2476756/Glaukos announced that it has entered into a licensing agreement with privately held, early-stage life sciences company Intratus. Under terms of the deal, Intratus has granted Glaukos a global exclusive license to
- Clearside Biomedical Announces Multiple Oral Presentations to be Given at the ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-announces-multiple-oral-presentations-to-be-given-at-the-asrs-annual-meeting/2476742/Clearside Biomedical announced that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector targeting the suprachoroidal space will be given at the upcoming American Society of Retinal Specialists (ASRS) annual meeting taking place July 26-30, 2019 in Chicago. <
- American Academy of Optometry Announces 2019 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2019-award-recipients/2476738/The American Academy of Optometry announced its 2019 award recipients, recognizing distinguished individuals who have made important contributions to advancing the profession of optometry: Raymond A. Applegate,
- Nicox Announces Completes Enrollment in NCX 470 Phase 2 Clinical Studyhttps://modernod.com/news/nicox-announces-completion-of-enrollment-in-ncx-470-phase-2-clinical-study-with-topline-results-on-track-for-early-4q-2019/2476734/Nicox SA announced that it has completed enrollment of patients in its multicenter, phase 2 clinical study evaluating NCX 470 nitric oxide (NO)-donating bimatoprost analog being tested in patients with open-angle glaucoma or ocular hypertension for its ability to lower IOP. This study is a head-t
- Ocular Therapeutix Announces Christopher White as Senior Vice President, Head of Business and Corporate Developmenthttps://modernod.com/news/ocular-therapeutix-announces-christopher-white-as-senior-vice-president-head-of-business-and-corporate-development/2476725/Ocular Therapeutix announced the appointment of Christopher White as Senior Vice President, Head of Business and Corporate Development. “We are thrilled to welcome Chris to the Ocular team to oversee business and corporate development,” Antony Mattessich, President and Chief Executive Offi
- Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMAhttps://modernod.com/news/omeros-announces-agreement-with-fda-on-primary-endpoint-for-narsoplimab-bla-in-stem-cell-transplant-associated-tma/2476724/Omeros announced agreement with the FDA on the response-based primary endpoint for its pivotal trial to support the biologics license application (BLA) for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), ac